Asia Fresh News

Asia Fresh Stories

Archive for February 23rd, 2017

Fortis Healthcare Partners With Excelity for Payroll and Benefits Administration

leave a comment »

MUMBAI, India /PRNewswire/ — Excelity Global, the largest Asia-based and India’s largest provider of payroll administration, benefits and human capital management, announced that it has been appointed as the payroll and benefits outsourcing partner to Fortis Healthcare. As a part of this strategic engagement, Excelity will leverage its HR outsourcing experience to manage payroll and benefits for 22,000+ colleagues within Fortis Healthcare and other group companies.

Commenting on this engagement, Sumit Sabharwal, CEO (Managed Services) said, “We have been awarded a multi-year partnership with Fortis, one of the world’s most respected healthcare companies. We take pride that Fortis has chosen Excelity as its partner of choice to manage their payroll and benefits administration. Organizations today are looking to streamline their payroll and benefits administration process while gaining process efficiencies and Excelity has been instrumental in doing this on a continuous basis.”

“We are happy to have partnered with Excelity on this journey. Excelity has demonstrated expertise in handing large payroll and benefits administration engagement in the past and they will leverage their expertise to deliver a world-class experience to our employees,” said Mr. Ranjan Pandey (Vice President, HR Operations), Fortis Healthcare.

He further said, “With this engagement, Excelity further strengthens its position as the largest payroll and benefits outsourcing service provider in the India market and in in key markets across Asia Pacific. Our focus continues to be transforming our client’s HR operations, incorporating smart technology, and improving their employee experience.”

About Excelity Global

Excelity Global is the largest Asia-based end-to-end HR solutions service provider with close to 2 decades years of experience and partnering with over 1,000 client entities helping them manage and administer their payroll and retrials functions more efficiently. Excelity Global services more than 1.2 Million employees per month and its current clientele includes top Global-Banks and Financial Institutions, e-commerce, utility, IT and FMCG corporations.

For more information, please visit: http://www.excelityglobal.com

About Fortis Healthcare

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 346 diagnostic centers.

For more information, please visit: http://www.fortishealthcare.com

Media Contacts
Jaya Jindal
jaya@80-db.com
+91-9654443463

Source: Excelity Global

Written by asiafreshnews

February 23, 2017 at 4:38 pm

Posted in Uncategorized

NeuroVive Pharmaceutical AB Year End Report January – December 2016

leave a comment »

STOCKHOLM /PRNewswire/ —

Important steps forward and new research collaborations

Business operations

Important events October – December 2016

  • The development of CicloMulsion for acute kidney injury was discontinued and as a consequence, the value of the subsidiary NeuroVive Asia was written-down by 50 percent and all previously capitalized expenditure in connection with CicloMulsion was recognized as an impaired value
  • New business model implemented which encompass out-licensing of projects for common indications, as well as proprietary development of orphan indication projects
  • Positive preclinical results obtained in an experimental model for non-alcoholic steatohepatitis (NASH), a very serious and common disease for which no medication is currently available
  • In a termination agreement, all rights for NV556 were returned to NeuroVive from Arbutus Biopharma. NeuroVive also received material manufactured by Arbutus valued at USD 1.5 million

Important events after the end of the period

  • The company’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells and the results were presented at a scientific conference
  • The company decided to redirect research resources from Asian subsidiary to parent. The operations in Taiwan have been sold to the current Taiwanese shareholder
  • A mitochondrial medicine research agreement regarding the NVP015 project was signed with US key opinion leader
  • A collaboration agreement was signed with Karolinska Institutet, Stockholm, Sweden, and the indication mitochondrial myopathy was added to the project portfolio

Financial information

Fourth quarter (October – December 2016)

  • Net revenues were SEK 14,000 (0) and other operating income was SEK 14,000 (23,000)
  • Loss before tax was SEK 14,580,000 (7,366,000)
  • Loss per share* was SEK 0.34 (1.75)
  • Diluted loss per share** was SEK 0.34 (1.75)

Twelve months (January-December 2016)

  • Net revenues were SEK 14,000 (2,502,000) and other operating income was SEK 104,000 (522,000)
  • Loss before tax was SEK 71,845,000 (90,801,000)
  • Loss per share* was SEK 1.67 (3.01)
  • Diluted loss per share** was SEK 1.67 (3.01)

*

Profit/loss for the period divided by the average number of shares before dilution at the end of the period.

**

Profit/loss for the period divided by the average number of shares after dilution at the end of the period.  

The complete Year End report is available for download below and through the NeuroVive web site www.neurovive.com.

For more information concerning this report, please contact:

Erik Kinnman
CEO
Telephone: +46 (0)46-275-62-20

This information is information that NeuroVive Pharmaceuticals (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 21 February 2017.

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.

NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund
Tel: 046-275-62-20 (switchboardl)
ir@neurovive.com
www.neurovive.com

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-year-end-report-january–december-2016,c2194299

The following files are available for download:

http://mb.cision.com/Main/6574/2194299/632155.pdf

NeuroVive Pharmaceutical – Year End report 2016

Source: NeuroVive Pharmaceutical
Related Links:

Written by asiafreshnews

February 23, 2017 at 4:12 pm

Posted in Uncategorized

Freepoint Commodities Grows its Presence in Asia

leave a comment »

Freepoint accelerates growth in the Asia-Pacific region by expanding its offices in Shanghai and Singapore

STAMFORD, Connecticut /PRNewswire/ — Freepoint Commodities LLC (“Freepoint”), a global commodities merchant trading house, today announced its expanded presence in the Asia-Pacific region. The initiative, the latest in a string of new ventures Freepoint has announced over the past six months, positions the firm to take advantage of opportunities it sees in the Asian metals, oil and agricultural markets.

“The decision to expand our presence in Asia was a logical next step in our business growth strategy,” said David Messer, CEO of Freepoint. “Asia in general, and China in particular, are integral to commodity markets, and we continue to demonstrate our commitment to the region through ongoing investment and product expansion.”

According to Rob Peck, Freepoint’s Global Head of Oil, “Asia continues to be the world’s largest oil demand region and leader in terms of the world’s demand growth. By adding an experienced Asia oil trading team led by Ouyang Xiuzhang and Khoo Teng Siong, we are confident we can better serve our clients in Asia. This is a terrific complement to Freepoint’s existing oil business in the Americas and Europe.”

Freepoint has added seventeen hires in Singapore and eight in Shanghai during Q4 2016 and January 2017. The additions bring the total number of Freepoint employees worldwide to over 350, spread across fourteen cities in six countries.

“Freepoint has provided customers with a metals offering since it acquired the metals and concentrates business from JP Morgan in 2012,” stated Philip Bacon, Head of Freepoint’s Metals and Concentrates business. “China represents half of the world’s metals demand. We are confident that adding the Shanghai-based refined metals team led by Ouyang will allow us to provide deeper and broader services to our clients in China and globally.”

Freepoint’s strategy centers on client service, and the firm consistently adds value by leveraging its global reach to solve its clients’ critical needs.

“Engaging key partners and creating enduring relationships has always been a hallmark of Freepoint’s business – a holdover from the management team’s history at Sempra Energy Trading. In keeping with this history, Freepoint is committed to its expansion in Asia and is continuing to build long-term partnerships with its clients in the region,” said Ouyang Xiuzhang, CEO of Freepoint’s Asia business.

About Freepoint Commodities LLC
Founded in 2011, Freepoint is based in Stamford, CT with over 350 employees worldwide.  Freepoint is a merchant of physical commodities and a financer of upper and mid-stream commodity assets.  Freepoint also provides physical supply services and related structured solutions for counterparties.  Freepoint is owned by private equity funds managed by Stone Point Capital, members of Freepoint’s management and senior employees.  More information about Freepoint can be found at http://www.freepoint.com.

Contact
Audrey Belloff
RF | Binder
+1 212 994 7547
audrey.belloff@rfbinder.com

 

Source: Freepoint Commodities LLC
Related Links:

Written by asiafreshnews

February 23, 2017 at 4:04 pm

Posted in Uncategorized

Mundipharma Helps Fight Common Colds with Introduction of BETADINE(R) Cold Defence

leave a comment »

— A natural product with anti-viral effects further extends the BETADINE® product range
— A new treatment that helps to eliminate 99% of cold and flu viruses and shortens the duration of common colds
— First time to market in Asia in formulations for adults and children

SINGAPORE /PRNewswire/ — Mundipharma, the makers of the BETADINE® range of products, has introduced a new early treatment to help families stay healthy and better compete in the perennial fight against common cold.

Professor Ronald Eccles at the BETADINE(R) Cold Defence launch media roundtable in Singapore
Professor Ronald Eccles at the BETADINE(R) Cold Defence launch media roundtable in Singapore

 

Common cold and flu-like illnesses are viral infections that affect adults twice per year on average. The impact is greater for children who can typically contract them up to five to seven times per year due to their close proximity at school and play.

Clinical trials have shown the treatment reduced duration of disease by up to two days, increased viral clearance and reduced severity of cold and flu-like symptoms in children and adults.

Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is an exciting development in the fight against the common cold.”

BETADINE® Cold Defence is a natural product with anti-viral effects that helps reduce duration of colds in adults and children. It is delivered as a nasal spray and contains the ingredient iota-carrageenan, also called Carragelose®. It is available in adult and children’s formulations and is recommended for use at the first sign of cold and flu-like symptoms.

Several large scale clinical trials involving close to 600 adult and pediatric patients were conducted to evaluate the efficacy and safety of the nasal spray. The analysis of children and adults suffering from virus-confirmed common cold after two randomized, double-blind, placebo-controlled trials the nasal spray appeared as an effective treatment of common cold.1

Raman Singh, President Mundipharma Asia Pacific, Latin America, Middle East and Africa, said “Every year the common cold interrupts family, school and working life, soaking up medical leave, putting pressure on productivity and colleagues and interrupting people’s daily life. As an early treatment to manage the Cold and other flu-like illnesses, BETADINE® Cold Defence can help keep families and workplaces productive and healthy.”

“The addition of BETADINE® Cold Defence to our BETADINE® range continues our commitment to the day-to-day wellbeing of families.”

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

About BETADINE®

The BETADINE® range of products is trusted by hospitals around the world for over 60 years to prevent and treat infections. A trusted brand among consumers at home to treat small wounds and grazes, sore throats, feminine infections and to stop minor problems from escalating into big issues. In-vitro studies show that BETADINE®medicines containing Povidone-Iodine kill a broad range of bacteria, viruses and fungi including antibiotic-resistant strains that cause infections. BETADINE® has four main categories of products in Wound Care, Feminine Care, Throat / Oral Care and Infectious Diseases to meet the varying needs of our customers.

® : BETADINE is a registered trademark of Mundipharma
® : Carregelose is a Registered Trademark of Marinomed.

Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.

[1] ‘Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold’, Tamas Fazekas, Philipp Eickhoff, Nathalie Pruckner, Georg Vollnhofer, Gustav Fischmeister, Christopher Diakos, Margit Rauch, Maria Verdianz, Andreas Zoubek, Helmut Gadner and Thomas Lion, BMC Complementary and Alternative Medicine, The official journal of the International Society for Complementary Medicine. Published, 5 September 2012.

Photo – http://photos.prnasia.com/prnh/20170222/8521701033
Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

Source: Mundipharma

Written by asiafreshnews

February 23, 2017 at 12:10 pm

Posted in Uncategorized